EMA Authorised: Izamby (denosumab) — Mabxience Research SL

View source ↗

Summary

EMA authorises Izamby (denosumab) for bone resorption disorders including osteoporosis and postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Resorption Disorders
• Osteoporosis
• Osteoporosis Postmenopausal

Drugs mentioned

• Izamby (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Mabxience Research SL. Decision date: 24/08/2026